BioSpace News Archive

Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS), a leading global IT services, consulting and business solutions organization, has announced the launch of the TCS COVID-19 Testing and Vaccine Management Suite

ControlRad, Inc., a privately held medical technology company focused on dramatically reducing unnecessary radiation exposure during fluoroscopically guided procedures, has announced the U.S. Food and Drug Administration (FDA) 510(k) clearance to market ControlRad Select

Fauna Bio today announced it has received a grant from the National Human Genome Research Institute (NHGRI) to investigate new ways to treat human diseases by studying the genetic makeup of other animals

Walmart commits $5 million over three years to the ADA to help diminish the health disparities gap for 122 million Americans living with diabetes and those at risk.

Quibim, a global leader in whole-body medical imaging analysis, announced the launch of qp-Prostate, its latest and most advanced prostate AI based Magnetic Resonance solution, after receiving 510 clearance by the US Food and Drug Administration.

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device designed to lower eye pressure for open-angle glaucoma patients, announced the first-ever release of five-year follow-up data from its HORIZON pivotal trial.

Gravity Diagnostics, a rapidly growing, CLIA-certified laboratory licensed in all 50 states, announced this week that they have received accreditation by the College of American Pathologists (CAP). Laboratories must meet stringent requirements around quality, accuracy, workflow processes, and scientific rigor during the process leading to CAP accreditation.

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that it has been selected by Sarepta Therapeutics, Inc. as a limited distribution partner for AMONDYS 45 (casimersen).

Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced that the last patient completed their last visit in the Phase 1/2 study evaluating Trappsol® Cyclo™